RAC1 function is also known to be essential in KRAS induced tumor formation (Kissil et al., 2007), and in KRAS oncogene addiction (Yuan et al., 2018), so the potential exists for SRF/MRTF inhibition to be explored in a far greater range of tumors than just RAC1P29S melanoma. This evidence concerns the gene RAC1 and neoplasm.